tetano
Editor, Senior Moderator
Br J Haematol
. 2022 Feb 16.
doi: 10.1111/bjh.18079. Online ahead of print.
Depletion of CD38-positive regulatory T cells by anti-CD38 monoclonal antibodies induces a durable response to SARS-CoV-2 vaccination in patients with plasma cell dyscrasia
Toshiki Terao[SUP] 1 [/SUP], Takashi Naduka[SUP] 2 [/SUP], Daisuke Ikeda[SUP] 1 [/SUP], Ami Fukumoto[SUP] 1 [/SUP], Yuya Kamura[SUP] 1 [/SUP], Ayumi Kuzume[SUP] 1 [/SUP], Rikako Tabata[SUP] 1 [/SUP], Takafumi Tsushima[SUP] 1 [/SUP], Daisuke Miura[SUP] 1 [/SUP], Kentaro Narita[SUP] 1 [/SUP], Masami Takeuchi[SUP] 1 [/SUP], Kosei Matsue[SUP] 1 [/SUP]
Affiliations
Abstract
This study reports the relationship between CD38[SUP]+[/SUP] regulatory T cells (Tregs) and messenger RNA coronavirus disease 2019 (mRNA-COVID-19) vaccination in 60 patients with plasma cell dyscrasia. Patients treated with anti-CD38 monoclonal antibodies (mAbs) had significantly lower CD38[SUP]+[/SUP] Tregs than those not treated (0.9 vs. 13.2/μl). Late-responders, whose antibody titres increased from weeks 4-12 after the second vaccination, had significantly lower CD38[SUP]+[/SUP] Treg counts than non-late-responders (2.5 vs. 10.3/μl). Antibody titres in patients with lower CD38[SUP]+[/SUP] Treg levels were maintained from weeks 4-12 but decreased in those with higher CD38[SUP]+[/SUP] Treg levels. Therefore, depletion of CD38[SUP]+[/SUP] Tregs by anti-CD38 mAbs may induce a durable response to mRNA-COVID-19 vaccination.
Keywords: anti-CD38 monoclonal antibody; coronavirus disease 2019 (COVID-19); multiple myeloma; regulatory T cell; vaccines.
. 2022 Feb 16.
doi: 10.1111/bjh.18079. Online ahead of print.
Depletion of CD38-positive regulatory T cells by anti-CD38 monoclonal antibodies induces a durable response to SARS-CoV-2 vaccination in patients with plasma cell dyscrasia
Toshiki Terao[SUP] 1 [/SUP], Takashi Naduka[SUP] 2 [/SUP], Daisuke Ikeda[SUP] 1 [/SUP], Ami Fukumoto[SUP] 1 [/SUP], Yuya Kamura[SUP] 1 [/SUP], Ayumi Kuzume[SUP] 1 [/SUP], Rikako Tabata[SUP] 1 [/SUP], Takafumi Tsushima[SUP] 1 [/SUP], Daisuke Miura[SUP] 1 [/SUP], Kentaro Narita[SUP] 1 [/SUP], Masami Takeuchi[SUP] 1 [/SUP], Kosei Matsue[SUP] 1 [/SUP]
Affiliations
- PMID: 35172374
- DOI: 10.1111/bjh.18079
Abstract
This study reports the relationship between CD38[SUP]+[/SUP] regulatory T cells (Tregs) and messenger RNA coronavirus disease 2019 (mRNA-COVID-19) vaccination in 60 patients with plasma cell dyscrasia. Patients treated with anti-CD38 monoclonal antibodies (mAbs) had significantly lower CD38[SUP]+[/SUP] Tregs than those not treated (0.9 vs. 13.2/μl). Late-responders, whose antibody titres increased from weeks 4-12 after the second vaccination, had significantly lower CD38[SUP]+[/SUP] Treg counts than non-late-responders (2.5 vs. 10.3/μl). Antibody titres in patients with lower CD38[SUP]+[/SUP] Treg levels were maintained from weeks 4-12 but decreased in those with higher CD38[SUP]+[/SUP] Treg levels. Therefore, depletion of CD38[SUP]+[/SUP] Tregs by anti-CD38 mAbs may induce a durable response to mRNA-COVID-19 vaccination.
Keywords: anti-CD38 monoclonal antibody; coronavirus disease 2019 (COVID-19); multiple myeloma; regulatory T cell; vaccines.